Abstract: A family of low-molecular-weight, main-chain thermotropic liquid-crystalline co-polyimides (TLC-CoPI) that are crosslinkable, and based on a unique, liquid-crystallinity (LC)-enabling diamine, namely, 1,3-bis[4-(4?-aminophenoxy)cumyl]benzene (BACB) and two or more mesogenic dianhydrides, at least one of which is a diphthalic dianhydride (DPA) that contains one or more thermally reactive and crosslinkable moieties similar to that of phenylethynyl (PE) is disclosed. Processes of making and using such low-molecular-weight, main-chain thermotropic liquid-crystalline co-polyimides are also provided.

Abstract: A family of low-molecular-weight, main-chain thermotropic liquid-crystalline polyimides (TLC-PI) that are crosslinkable is disclosed. These all-aromatic TLC-PI are derived from (i) wholly aromatic and flexible diamine monomers, in which the linkage between the two aniline-ends contains a relatively high heat-tolerant but flexible chain constituted by two or more units of 1,4-phenoxy or 1,3-phenoxy or in combinations of both. Processes of making and using such all-aromatic TLC-PI is also provided.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.

Abstract: A family of low-molecular-weight, main-chain thermotropic liquid-crystalline co-polyimides (TLC-CoPI) that are crosslinkable, and based on a unique, liquid-crystallinity (LC)-enabling diamine, namely, 1,3-bis[4-(4?-aminophenoxy)cumyl]benzene (BACB) and two or more mesogenic dianhydrides, at least one of which is a diphthalic dianhydride (DPA) that contains one or more thermally reactive and crosslinkable moieties similar to that of phenylethynyl (PE) is disclosed. Processes of making and using such low-molecular-weight, main-chain thermotropic liquid-crystalline co-polyimides are also provided.

Abstract: Applicants disclose a family of low-molecular-weight, main-chain thermotropic liquid-crystalline polyimides (TLC-PI) that are thermally crosslinkable and processes of making and using same. Such materials provide flexibility advantage when modifying ink materials to meet varying processing conditions in additive manufacturing of devices and components that require high-temperature polymers.

Abstract: Methods, apparatus, systems and articles of manufacture are disclosed. An example vehicle disclosed herein includes a steering assist system, a steering wheel, and a steering controller to detect a request to move the steering wheel of the vehicle to a first rotational position, the steering wheel having a second rotational position, actuate, via the steering assist system, the steering wheel towards the first rotational position, determine, based on a relationship between a first parameter and a second parameter, a third rotational position, the third rotational position having an angular offset from the first rotational position, the first parameter corresponding to a position of the steering system, the second parameter corresponding to a load on the steering system, and in response to reaching the third rotational position, disengage the steering assist system, the disengagement causing the steering wheel to rotate to the first rotational position.

Abstract: The present invention relates to novel Fused Bicyclic Pyrazole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are as defined herein. The present invention also relates to compositions comprising at least one Fused Bicyclic Pyrazole Derivative, and methods of using the Fused Bicyclic Pyrazole Derivatives for treating or preventing a herpesvirus infection in a patient.

Abstract: A primer set for detecting telomerase activity, the primer set including a first primer set or a second primer set. The first primer set includes: an upstream primer selected from MTS; and a downstream primer selected from the group consisting of ACX-M4, Beacon ACX62-2C, and Beacon ACX62-10. The second primer set includes: an upstream primer selected from STS or CTS; and a downstream primer selected from the group consisting of ACX, CXT, ACX-M4, Beacon ACX62-2C, or Beacon ACX62-10. The sequences of the primers ACX, CXT, ACX-M4, Beacon ACX62-2C, Beacon ACX62-10, STS, CTS and MTS are shown as SEQ ID NOs: 1 to 8, respectively.

Abstract: Provided is a co-attrited MCC/CMC stabilizer composition containing MCC made from non-dissolving cellulose pulps that is useful for stabilizing plant protein based drinks. Also provided are plant protein drink compositions stabilized using the co-attrited MCC/CMC stabilizer composition containing MCC made from non-dissolving cellulose pulps. Also provided are methods of stabilizing plant protein drink compositions using the co-attrited MCC/CMC stabilizer composition containing MCC made from non-dissolving cellulose pulps.

Abstract: A polypeptide probe for detecting G-quadruplexes (G4s), includes: from two to four G4-binding domains, and one or more linkers disposed between every two G4-binding domains. Each G4-binding domain includes a specific motif including a sequence of amino acids PGHLKGREIGMWY (SEQ ID NO: 1).

Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.

Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.

Abstract: Methods, apparatus, systems and articles of manufacture are disclosed. An example vehicle disclosed herein includes a steering assist system, a steering wheel, and a steering controller to detect a request to move the steering wheel of the vehicle to a first rotational position, the steering wheel having a second rotational position, actuate, via the steering assist system, the steering wheel towards the first rotational position, determine, based on a relationship between a first parameter and a second parameter, a third rotational position, the third rotational position having an angular offset from the first rotational position, the first parameter corresponding to a position of the steering system, the second parameter corresponding to a load on the steering system, and in response to reaching the third rotational position, disengage the steering assist system, the disengagement causing the steering wheel to rotate to the first rotational position.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.

Abstract: This invention relates to making and using a stabilizer that is effective in small amounts and, particularly useful for stabilizing low solids liquids, e.g., dispersions, emulsions, and suspensions, used in foods, pharmaceuticals, nutraceuticals, and similar industrial applications, which comprises, microcrystalline cellulose, (preferably, colloidal hydrolyzed MCC); a first carboxymethyl cellulose having a viscosity of 30-85 cP at 2% in deionized water; and, a degree of carboxymethyl substitutions of 0.60 to 0.85, and a second carboxymethyl cellulose having a viscosity of 400-800 cP at 2% in deionized water, and a degree of carboxymethyl substitutions of 0.80 to 0.

Abstract: Methods and apparatus are disclosed herein to center a steering wheel. An example vehicle includes a steering assistance system, an axle including a wheel, memory, and a processor to execute instructions to identify a first position of the wheel, detect a request to move the wheel to a second position, adjust the wheel from the first position to the second position via the steering assistance system, disengage the steering assistance system, the disengagement of the steering assistance system to cause the wheel to move to a third position, the third position offset from the second position by an angular offset in a first direction, adjust the wheel to a fourth position, the fourth position offset from the second position by the angular offset in a second direction different than the first direction, and disengage the steering assistance system, the disengagement of the steering assistance system to cause the wheel to move to the second position..

Abstract: Embodiments disclosed herein provide enzymatic formulations comprising a polypeptide having amylase activity for producing a paper product. Also provided are aqueous surface treatment compositions for paper and board comprising degraded starch. Further provided are methods for producing paper and board using the aqueous surface treatment composition, and to corrugated boards produced from this paper.

Abstract: A polypeptide probe, including: from two to four G4-binding domains, and one or more linkers disposed between every two G4-binding domains. Each G4-binding domain includes a specific motif including a sequence of amino acids (SEQ?ID?NO:?1) PGHLKGREIGMWY.

Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.

Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.